In silico
Clinical trials of a drug for lung fibrosis created by AI have begun
Svetlana Maslova, Hi-tech+
The experimental drug ISM001-055 has developed artificial intelligence, the algorithm of which was created by scientists from the company Insilico Medicine, writes EurekAlert. Currently, there are no targeted drugs for the treatment of idiopathic pulmonary fibrosis and a new candidate can make a difference for thousands of patients.
The experimental drug ISM001-055 has developed artificial intelligence, the algorithm of which was created by scientists from the company Insilico Medicine, writes EurekAlert. Currently, there are no targeted drugs for the treatment of idiopathic pulmonary fibrosis and a new candidate can make a difference for thousands of patients.
Pilot clinical trials on eight volunteers showed favorable pharmacokinetics and safety profile of ISM001-055. Now scientists have announced the launch of the first phase of a clinical trial involving 80 volunteers from 18 to 65 years old.
It is planned to evaluate ten different dosages of the drug, which will be administered orally.
The authors especially emphasize that AI was able not only to identify a new therapeutic target, but also to develop a potentially effective drug for it, according to previously conducted preclinical trials. The final results of the first phase of research will be presented in a year.
Idiopathic pulmonary fibrosis, in which scar tissue forms in place of healthy tissue, refers to chronic diseases. Progressing, the disease gradually reduces lung function. The exact causes of the disease have not been established, but genetics and smoking are considered the most likely.
Recently, scientists from the United States also presented an experimental therapy that, with the help of stem cells, helped to cope with already formed scars in mice.
Portal "Eternal youth" http://vechnayamolodost.ru